Total raised
$26.2M
Last: Undisclosed 2016-02
Stage
Series A
Founded
2010
Headcount
1-10
HQ
Yavne
Sector
Health Tech & Life Sciences
About
Avraham Pharmaceuticals is an emerging pharmaceutical company developing novel products for the treatment and prevention of neurodegenerative disorders such as Alzheimer's disease, Lewy body disease, and Parkinson's disease. The company's lead product candidate, Ladostigil, was exclusively in-licensed from the Hebrew University and the Technion and is in phase 2 clinical studies for mild cognitive impairment (MCI). Ladostigil is a multifunctional compound that combines neuro-protective mechanisms, reducing oxidative stress and microglial activation while inhibiting pro-inflammatory cytokines. Ladostigil may have the potential to slow the progression of Alzheimer's disease in patients diagnosed with MCI.
Funding history · 5 rounds · $26.2M total
2016-02
Undisclosed
$4.0M
2014-09
Undisclosed
$4.5M
2013-02
Undisclosed
$5.7M
2011-11
Undisclosed
$3.0M
2010-07
Series A
$9.0M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
alzheimers-diseasedegenerative-diseasesneurologypharmaceuticalspharma-companiesseniorsparkinson